Tafenoquine treatment of Plasmodium vivax malaria: suggestive evidence that CYP2D6 reduced metabolism is not associated with relapse in the Phase 2b DETECTIVE trial. (Q36591835)
Jump to navigation
Jump to search
scientific article published on 18 February 2016
Language | Label | Description | Also known as |
---|---|---|---|
English | Tafenoquine treatment of Plasmodium vivax malaria: suggestive evidence that CYP2D6 reduced metabolism is not associated with relapse in the Phase 2b DETECTIVE trial. |
scientific article published on 18 February 2016 |
Statements
Tafenoquine treatment of Plasmodium vivax malaria: suggestive evidence that CYP2D6 reduced metabolism is not associated with relapse in the Phase 2b DETECTIVE trial (English)
Pamela L St Jean
Zhengyu Xue
Nick Carter
Stephan Duparc
Maxine Taylor
Claire Beaumont
Ronnatrai Rueangweerayut
Justin A Green
Srivicha Krudsood
1 reference